(0.11%) 5 254.35 points
(0.12%) 39 807 points
(-0.12%) 16 379 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(1.45%) $922.85
(0.07%) $0.927
(0.19%) $10.86
(-0.03%) $0.792
(-0.03%) $92.55
Quarter results today
(bmo 2024-03-29)
Expected move: +/- 0.00%
Live Chart Being Loaded With Signals
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China...
Stats | |
---|---|
Today's Volume | 32.72M |
Average Volume | 49.27M |
Market Cap | 55.57B |
EPS | HKD0 ( 2023-08-25 ) |
Next earnings date | ( HKD0 ) 2024-03-29 |
Last Dividend | HKD0.0600 ( 2023-06-20 ) |
Next Dividend | HKD0 ( N/A ) |
P/E | 27.45 |
ATR14 | HKD0.0100 (0.33%) |
Volume Correlation
Sino Biopharmaceutical Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Sino Biopharmaceutical Correlation - Currency/Commodity
Sino Biopharmaceutical Financials
Annual | 2022 |
Revenue: | HKD28.78B |
Gross Profit: | HKD22.98B (79.86 %) |
EPS: | HKD0.270 |
Q3 | 2023 |
Revenue: | HKD0 |
Gross Profit: | HKD0 (0.00 %) |
EPS: | HKD0 |
Q2 | 2023 |
Revenue: | HKD7.64B |
Gross Profit: | HKD6.01B (78.68 %) |
EPS: | HKD0.0339 |
Q1 | 2023 |
Revenue: | HKD7.64B |
Gross Profit: | HKD6.01B (78.68 %) |
EPS: | HKD0.0339 |
Financial Reports:
No articles found.
Sino Biopharmaceutical Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0.0600 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
HKD0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | HKD0.00198 | 2004-09-16 |
Last Dividend | HKD0.0600 | 2023-06-20 |
Next Dividend | HKD0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 70 | -- |
Total Paid Out | HKD0.573 | -- |
Avg. Dividend % Per Year | 0.00% | -- |
Score | 4.04 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.15 | |
Div. Directional Score | 7.79 | -- |
Year | Amount | Yield |
---|
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
3877.HK | Ex Dividend Knight | 2023-06-28 | Semi-Annually | 0 | 0.00% | |
1763.HK | Ex Dividend Knight | 2023-07-04 | Annually | 0 | 0.00% | |
0811.HK | Ex Dividend Knight | 2023-05-22 | Annually | 0 | 0.00% | |
2333.HK | Ex Dividend Junior | 2023-06-29 | Annually | 0 | 0.00% | |
1319.HK | Ex Dividend Knight | 2023-08-02 | Semi-Annually | 0 | 0.00% | |
0388.HK | Ex Dividend Knight | 2023-08-29 | Semi-Annually | 0 | 0.00% | |
6119.HK | Ex Dividend Junior | 2023-06-06 | Annually | 0 | 0.00% | |
1881.HK | Ex Dividend Junior | 2023-05-11 | Semi-Annually | 0 | 0.00% | |
0914.HK | Ex Dividend Junior | 2023-06-02 | Annually | 0 | 0.00% | |
0052.HK | Ex Dividend Knight | 2023-09-12 | Semi-Annually | 0 | 0.00% |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.0711 | 1.500 | 8.58 | 10.00 | [0 - 0.5] |
returnOnAssetsTTM | 0.0239 | 1.200 | 9.20 | 10.00 | [0 - 0.3] |
returnOnEquityTTM | 0.0526 | 1.500 | -0.527 | -0.791 | [0.1 - 1] |
payoutRatioTTM | 0.404 | -1.000 | 5.96 | -5.96 | [0 - 1] |
currentRatioTTM | 1.004 | 0.800 | 9.98 | 7.98 | [1 - 3] |
quickRatioTTM | 0.848 | 0.800 | 9.72 | 7.77 | [0.8 - 2.5] |
cashRatioTTM | 0.431 | 1.500 | 8.72 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.176 | -1.500 | 7.07 | -10.00 | [0 - 0.6] |
interestCoverageTTM | 0 | 1.000 | -1.111 | -1.111 | [3 - 30] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.93 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.385 | -1.500 | 8.46 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.788 | 1.000 | 0.197 | 0.197 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.203 | 1.000 | 7.94 | 7.94 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.331 | 1.000 | 9.27 | 9.27 | [0.2 - 2] |
assetTurnoverTTM | 0.336 | 0.800 | -1.092 | -0.873 | [0.5 - 2] |
Total Score | 10.44 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 34.96 | 1.000 | 6.57 | 0 | [1 - 100] |
returnOnEquityTTM | 0.0526 | 2.50 | -0.339 | -0.791 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 0.142 | 2.00 | 9.95 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 2.84 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 0.196 | 2.00 | 9.93 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.404 | 1.500 | 5.96 | -5.96 | [0 - 1] |
pegRatioTTM | 0.362 | 1.500 | -0.920 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.174 | 1.000 | 8.16 | 0 | [0.1 - 0.5] |
Total Score | 5.15 |
Sino Biopharmaceutical
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company's products include oncology medicines comprising Qingkeshu tablets, Anxian capsules, Yinishu tablets, Genike capsules, Anyue capsules, and Leweixin injections; cardio-cerebral vascular medicines, including Kaina and Anrixin tablets; hepatitis medicines, such as Tianqingganmei injections and Tianqingganping enteric capsules; orthopedic medicines consisting of Gaisanchun capsules, Yigu injections, and Taiyan tablets; respiratory system medicines; parenteral nutritious medicines comprising Xinhaineng and Fenghaina injections; and other medicines, including Tuotuo tablets, Debaian cataplasms, and Qingliming injections. It also offers Aprepitant capsules, Lenvatinib Mesilate capsules, Vortioxetine Hydrobromide tablets, Edaravone injection, Amlodipine Besylate and Atorvastatin Calcium tablets, Sofosbuvir tablets, Sitagliptin Phosphate tablets, Colistimethate Sodium for injection, and Tofacitinib Citrate tablets. In addition, the company holds properties; retails and distributes pharmaceutical products; offers optometry for optical glasses and sells ophthalmic products; operates hospitals; provides medical management and health information consultancy, as well as bio-tech transfer and consultation services; manufactures and sells health food; and offers orthopedic outpatient and surgical procedures. Further, it manufactures, sells, and distributes health food; develops medical and health technology; trades in optical glasses; and researches, develops, and sells medical devices and active pharmaceutical ingredients. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators